Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 2012: Case Study  

Recovery of residual curarization after red blood cell transfusion

Veit-Simon Eckle BDEF , Eckhard Schmid BDE , Tanja Fehm BDE , Christian Grasshoff BDEF

DOI: 10.12659/MSM.883530

Med Sci Monit 2012; 18(11): CS91-93

0 Comments

Background

The rapid action of succinylcholine makes this depolarizing muscle relaxant favorable for facilitating tracheal intubation in emergency patients and clinical situations with high aspiration risk [1]. The neuromuscular blocking effects of succinylcholine and mivacurium are terminated by rapid hydroxylation by the butyrylcholinesterase enzyme (BChE; plasma cholinesterase) [2,3]. Unfortunately, approximately 25% of individuals in a white population have a hereditary variation of the enzyme, extending the neuromuscular blocking effects of both muscle relaxants up to several hours [4,5]. Apart from genetic variability, acquired diseases such as hepatic failure or physiologic changes during pregnancy are known to reduce the amount of plasma cholinesterase or the efficiency of its enzymatic action [6]. Therapeutic alternatives are few; either the patients are ventilated for 4–8 hours until the end of prolonged neuromuscular block, or injection of cholinesterase may lead to a shorter duration of action of the neuromuscular blocking agent mivacurium [7]. Here, we report a parturient woman with severe atonic bleeding and prolonged succinylcholine block after uterine abrasion under general anesthesia, whose prolonged muscle relaxation was terminated by application of packed red cells.

Case Report

A 31-year-old parturient woman (70 kg body weight) without history of previous anesthesia was admitted to the hospital with atonic bleeding after 25-hour labor preceding successful delivery at home. In order to replace perinatal blood loss, 1 L colloid and 1 L crystalloid solution were given by the emergency team before the patient arrived at the hospital. At admission the patient appeared fully conscious, and heart rate [HR] and blood pressure [BP] were measured to be 90 beats·min−1 and 120/60 mmHg, respectively. Blood gas analysis revealed a hemoglobin level as low as 6.0 g·dL−1. Prompt uterine curettage was required, as bleeding was sustained. After rapid sequence induction of general anesthesia with 200 mg propofol, 100 mg succinylcholine (1.25 mg·kg−1), and 1 mg rapifen, the tubus was successfully placed into the trachea. During general anesthesia maintained with sevoflurane (1.5 Vol-%), blood pressure and heart rate remained stable, obviating the need for immediate blood transfusion with AB0-untested red packed cells. As blood coagulation appeared to be clinically impaired, 4 g fibrinogen and 2 g tranexamic acid were given intravenously. Removal of residual placenta was complicated by a retroflected uterus, prolonging the surgical procedure to 105 minutes. After extubation of the trachea at stable cardiovascular conditions, the HR increased to 140 bpm, the tongue was obstructing the airway, and tachydyspnoea could be observed. Oxygenation was maintained by applying jaw thrust and supply of 100% oxygen using a face mask. Neuromuscular monitoring, manually tested, showed no fading of the “train of four”, thereby excluding dual block. The patient was awake but she could not open her eyes or give hand signs. Furthermore, uncoordinated muscle activity was visible. As at this time, automatic BP stopped measuring values in a detectable range, making blood loss the most likely cause. Consequently, AB0-compatible red blood cells (250 mL) were transfused at high flow by using a pressure bag and a warming system (Ranger®). While reinduction of general anesthesia was prepared, the patient immediately regained neuromuscular function, tachydyspnoea stopped, and she was able to open her eyes, give hand signs, and speak. Simultaneously, the HR decreased to 90 beats·min−1 and automatic BP displayed values in the normal range, enabling transfer to the intermediate care unit.

The following morning, plasma cholinesterase level was 3.200 U·L−1, which is below the normal range (4.900–12.000 U·L−1), and the patient’s blood DNA testing revealed that she was a heterozygous carrier of the K variant of plasma cholinesterase.

Discussion

In our patient, signs of physical stress and the inability fof automatic blood pressure measurement (probably due to shivering) were misinterpreted to be caused by intravascular volume deficiency, in particular as a hemoglobin level as low as 6.0 g·dL−1. Retrospectively, it became clear that she had a prolonged action of succinylcholine due to a genetic variation, namely, the K variant of the butyrylcholinesterase enzyme. The frequency of the K variant of plasma cholinesterase is described to be at 13%, and the enzyme activity is typically decreased by 30% [8]. Even in patients carrying the heterozygous K variant, effects of mivacurium or succinylcholine might be prolonged [9,10]. Pregnancy and hemodilution as a result of volume therapy might have further contributed to decreased plasma cholinesterase activity. Furthermore, significantly lower levels of plasma cholinesterase are described to occur in up to 10% of parturients [11].

It can be assumed that the immediate improvement of neuromuscular distress was either caused by plasma cholinesterase in the residual serum of packed red cells, or by release from hemolyzed erythrocytes. Epstein et al have shown that the activity of serum cholinesterase in stored whole blood was around 87% of initial values after 21 days [12]. It has been demonstrated in patients with K variant that administration of plasma cholinesterase reverses the effect of mivacurium [7]. Further, Lainé-Cessac et al. measured cholinesterase activity in erythrocytes and plasma by hydrolysis of acetyl-, butyryl-, and succinylcholine [13]. Erythrocyte acetylcholinesterase was tested after red cells were hemolyzed. Determination of activity correlated well among the 3 substrates (r>0.94), with erythrocyte acetylcholinesterase being 3.7-fold more effective compared to plasma cholinesterase [13]. Our patient recovered, most probably due to transfusion of red blood cells, which were hemolyzed in part by high speed transfusion, leading to an increase in serum potassium from 4.4 mmol·L−1 to 5.7 mmol·L−1 after transfusion. Lovely et al reported a patient with compromised plasma cholinesterase activity undergoing first surgery without prolonged succinylcholine blockade, but experiencing it after a second intervention [14]. The authors assumed that packed red blood cells given perioperatively masked atypical plasma cholinesterase the first time succinylcholine was administered. In another study, concentrations of the short-acting opioid remifentanil were lower when incubated with red blood cells compared to plasma incubation, suggesting a role of erythrocyte cholinesterase in remifentanil esterase-dependent metabolism [15]. Moreover, in organophosphorus poisoning, erythrocyte cholinesterase might be a bioscavenger when given as whole blood transfusion, as reported by Ryniak et al. [16].

In addition to the K variant of plasma cholinesterase, there are other genetic mutations, like the atypical (A) and silent (S) variant, with different impact on enzyme activity [17,18]. Although the modest reduction of plasma cholinesterase due to the K variant (67% of normal enzyme activity) usually does not cause significant prolongation of succinylcholine effect, the combination with another variant, chronic illness, organophosphorus poisoning, or, as in our case, pregnancy and major blood loss, might lead to clinical appearance [4,8,19]. This is in line with the study of Levano et al, who genotyped 9 patients with prolonged neuromuscular block after succinylcholine, but 2 of them displayed normal molecular genetic results [4].

Conclusions

Anesthesiologists should be aware of lower levels of plasma cholinesterase occurring in parturient women [6]. Application of succinylcholine or mivacurium in these patients must be carefully considered, since rapid-sequence induction can be performed alternatively with rocuronium [20–22]. The routine use of red blood cells to determine prolonged muscle dysfunction is certainly not recommended, but it helped in the case reported.

References

1. El-Orbany M, Connolly LA, Rapid sequence induction and intubation: current controversy: Anesth Analg, 2010; 110; 1318-25, pmid: 20237045

2. Lien CA, Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents: Br J Anaesth, 2011; 107(Suppl 1); i60-71, pmid: 22156271

3. Li Wan Po A, Girard T, Succinylcholine: still beautiful and mysterious after all these years: J Clin Pharm Ther, 2005; 30; 497-501, pmid: 16336279

4. Levano S, Ginz H, Siegemund M, Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine: Anesthesiology, 2005; 102; 531-35, pmid: 15731589

5. Lockridge O, Masson P, Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk: Neurotoxicology, 2000; 21; 113-26, pmid: 10794391

6. Davis L, Britten J, Morgan M, Cholinesterase. Its significance in anaesthetic practice: Anaesthesia, 1997; 52; 244-60, pmid: 9124666

7. Østergaard D, Viby-Mogensen J, Rasmussen SN, Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: Effect of injection of human cholinesterase: Anesthesiology, 2005; 102; 1124-32, pmid: 15915024

8. Bartels C, Jensen F, Lockridge O, DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites: Am J Hum Genet, 1992; 50; 1086-103, pmid: 1570838

9. Gätke MR, Viby-Mogensen J, Østergaard D, Bundgaard JR, Response to mivacurium in patients carrying the K variant in the butyrylcholinesterase gene: Anesthesiology, 2005; 102; 503-8, pmid: 15731585

10. Mollerup HM, Gätke MR, Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy: Acta Anaesthesiol Scand, 2011; 55; 82-86, pmid: 21029050

11. Shnider S, Serum cholinesterase activity during pregnancy, labor and the puerperium: Anesthesiology, 1965; 26; 335-39, pmid: 14289955

12. Epstein HM, Jarzemsky D, Zuckerman L, Vagher P, Plasma Cholinesterase Activity in Bank Blood: Anesth Analg, 1980; 59; 211-14, pmid: 7189352

13. Lainé-Cessac P, Turcant A, Allain P, Automated determination of cholinesterase activity in plasma and erythrocytes by flow-injection analysis, and application to identify subjects sensitive to succinylcholine: Clin Chem, 1989; 35; 77-80, pmid: 2910584

14. Lovely MJ, Patteson SK, Beuerlein FJ, Chesney JT, Perioperative blood transfusion may conceal atypical pseudocholinesterase: Anesth Analg, 1990; 70; 326-27, pmid: 2305986

15. Davis PJ, Stiller RL, Wilson AS: Anesth Analg, 2002; 95; 1305-7, pmid: 12401616

16. Ryniak S, Harbut P, GoŸdzik W, Whole blood transfusion in the treatment of an acute organophosphorus poisoning – a case report: Med Sci Monit, 2011; 17(9); CS109-11, pmid: 21873952

17. Panhuizen IF, Snoeck MM, Levano S, Girard T, Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity: Case Report Med, 2010; 2010; 472389, pmid: 20589221

18. Gätke MR, Bundgaard JR, Viby-Mogensen J, Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia: Pharmacogenet Genomics, 2007; 17; 995-99, pmid: 18075469

19. Garcia DF, Oliveira TG, Molfetta GA, Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine: Genet Mol Biol, 2011; 34; 40-44, pmid: 21637541

20. Williamson RM, Mallaiah S, Barclay P, Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia: Acta Anaesthesiol Scand, 2011; 55; 694-99, pmid: 21480829

21. Perry JJ, Lee JS, Sillberg VA, Wells GA, Rocuronium versus succinylcholine for rapid sequence induction intubation: Cochrane Database Syst Rev, 2008(2); CD002788, pmid: 18425883

22. Sharp LM, Levy DM, Rapid sequence induction in obstetrics revisited: Curr Opin Anaesthesiol, 2009; 22; 357-61, pmid: 19434777

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750